tiprankstipranks
Liminatus Pharma, Inc. (LIMN)
NASDAQ:LIMN
US Market
LIMN
Liminatus Pharma
RESEARCH TOOLSreports
Want to see LIMN full AI Analyst Report?

Liminatus Pharma (LIMN) Income Statement

88 Followers

Liminatus Pharma Income Statement

Last quarter (Q4 2025), Liminatus Pharma's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Liminatus Pharma's net income was $-8.17M. See Liminatus Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 2.97M$ 2.91M$ 2.59M$ 2.71M$ 2.53M
Depreciation and Amortization
$ 1.83K$ 0.00$ 0.00$ 0.00$ 0.00
EBITDA
$ -9.99M$ -2.75M$ -1.09M$ -2.71M$ 4.37M
Operating Income
$ -2.97M$ -2.91M$ -2.59M$ -2.71M$ -2.53M
Other Income/Expenses
$ -7.24M$ 20.86K$ 1.39M$ -219.00K$ 6.90M
Pretax Income
$ -10.21M$ -2.89M$ -1.19M$ -2.93M$ 4.37M
Net Income
$ -10.21M$ -2.90M$ -1.23M$ -2.93M$ 4.37M
Per Share Metrics
Basic EPS
$ -0.43$ -0.40$ -0.15$ -0.08$ 0.13
Diluted EPS
$ -0.43$ -0.40$ -0.15$ -0.08$ 0.13
Weighted Average Shares Outstanding
 23.75M 7.19M 8.01M 34.43M 34.50M
Weighted Average Shares Outstanding (Diluted)
 23.75M 7.19M 8.01M 34.43M 34.50M
Currency in USD

Liminatus Pharma Earnings and Revenue History